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ABSTRACT
Introduction. Sorafenib is an oral multikinase inhibitor
that targets Raf kinase and receptor tyrosine kinases
and has led to a longer median overall survival (OS)
time and time to progression (TTP) in patients with ad-
vanced hepatocellular carcinoma (HCC). This study
was conducted to assess the link between the antitumor
efficacy of sorafenib and its early cutaneous side effects
in advanced HCC patients.
Materials and Methods. All patients received 800 mg
daily of sorafenib until progression or unacceptable tox-
icities. We retrospectively analyzed the incidence of
rash and hand–foot skin reactions (HFSR) during the
first month of treatment, comparing tumor control
(partial response plus stable disease) and TTP.
Results. Sixty-five HCC patients treated with sor-
afenib were included in this analysis: 47 (73.3%) re-
ceived sorafenib after failure of some local treatment,
whereas 18 (27.7%) received it as first-line treatment.
Twenty-nine patients developed at least grade 1 skin tox-
icity (rash, 13; HFSR, 16). In patients who developed skin
toxicity, the tumor control rate was 48.3%, versus 19.4%
in patients without cutaneous side effects. The median
TTP was 8.1 months in the group of patients with skin tox-
icity versus 4.0 months in those without skin toxicity. This
difference was also statistically significant on multivariate
analysis. A borderline statistically significant difference
was also observed in terms of OS in patients with early skin
toxicity.
Conclusions. Skin toxicity should be closely moni-
tored in HCC patients treated with sorafenib in relation
to its potential role as a surrogate marker of efficacy.
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INTRODUCTION
Nowadays, hepatocellular carcinoma (HCC) treatment still
represents a considerable challenge. Surgery, including liver
transplantation, is the most important therapeutic option for
patients with this disease, but unfortunately it can be consid-
ered a possible approach only in patients with a good perfor-
mance status and early-stage HCC. Most of the patients
affected by HCC still have a poor prognosis, and new thera-
peutical possibilities are needed to face this aggressive disease.
Sorafenib is an oral multikinase inhibitor that has shown
potent in vitro activity by targeting the Raf/mitogen-activated
protein kinase/extracellular signal–related kinase signaling
pathway. Sorafenib inhibits cell surface tyrosine kinase recep-
tors (vascular endothelial growth factor receptor [VEGFR]-2,
VEGFR-3, and platelet-derived growth factor receptor ) and
downstream intracellular serine/threonine kinases (Raf-1,
wild-type B-Raf, and mutant B-Raf) involved in both tumor
cell proliferation and tumor angiogenesis [1]. Sorafenib first
came to attention in early clinical trials enrolling patients with
refractory solid tumors. It is approved today for the treatment
of advanced renal cancer in patients previously treated with in-
terferon- or interleukin-2, or when these first-line therapies
are considered unsuitable. More recently, sorafenib was found
to have significant clinical activity against HCC in phase II and
phase III studies [2, 3], in which it was found to lead to a longer
median survival time and time to radiologic progression when
compared with placebo. As well as significant activity, sor-
afenib is characterized by a good tolerability profile. The main
side effects associated with sorafenib are diarrhea, nausea, fa-
tigue, hypertension, and dermatological toxicities including
alopecia, stomatitis, erythema, and hand–foot skin reaction
(HFSR).
HFSR (Table 1) is a cutaneous reaction characterized by
erythema, numbness, tingling, and dysesthesia or paresthesia,
particularly on the palms and soles. Swelling of the skin, des-
quamation, ulceration, or blistering may occur in advanced
cases [4]. HFSR is often also referred to as hand–foot syn-
drome (HFS) and palmar–plantar erythrodysesthesia. Al-
though the literature suggests some differences between
HFSR and HFS [5, 6], up to today the evidence does not seem
to be sufficiently convincing to make this distinction. In this
manuscript we have opted to refer to the toxicity as HFSR.
The aim of the present retrospective study was to ex-
plore the potential association between HFSR and efficacy
in HCC patients treated with sorafenib.
MATERIALS AND METHODS
Patients with a histologically confirmed diagnosis of HCC
and advanced disease not suitable for locoregional treat-
ments were analyzed. Other inclusion criteria were: age
18 years; performance status score of 0 or 1; Child–Pugh
(CP) class A or B; life expectancy 12 weeks; and ade-
quate hematologic, hepatic, and renal function. Hepatitis B
virus (HBV) or hepatitis C virus (HCV) infection status at
baseline was collected from medical history or laboratory
tests.
Standard criteria for anticancer treatment suitability for
all patients were used. In particular, renal function was
evaluated, and only patients within the normal range (serum
creatinine, 0.8–1.44 mg/dl) were included. Thyroid func-
tion was also studied.
Patients were considered ineligible for this analysis if
they had reported fever (body temperature 38.0°C) dur-
ing the last week before study entry, in order to avoid con-
founding factors influencing the presence and the severity
of side effects, or had received any radiotherapy, chemo-
therapy, immunotherapy, or growth factors during the last 4
weeks before the analysis. Patients recently (1 week) or
simultaneously treated with chronic steroid-based therapy,
affected by acute or chronic infection or inflammatory dis-
eases or with a previous medical history suggestive of
chronic rashes were considered ineligible for the study. We
compared tumor control (partial response plus stable dis-
ease), time to progression (TTP), and overall survival (OS)
in patients who developed at least grade 1 rash or HFSR and
Table 1. Hand–foot skin reaction
Grade 0 None
Grade 1 ● Numbness
● Unpleasant sensations when touching
ordinary things
● Burning or prickling feeling
● Tingling
● Painless swelling
● Redness or discomfort of hands or feet
Grade 2 One or more of the following:
● Painful redness
● Swelling
● Skin thickening of the hands or feet
Symptoms create discomfort but do not affect
the patient’s normal daily activities
Grade 3 One or more of the following:
● Scaling or shedding of skin
● Open sores
● Blistering
● Skin thickening
● Severe pain of the hands and feet
Severe discomfort that causes the patient to be
unable to work or perform daily activities
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patients who did not present any reaction. The starting date
of the study was November 2007 and the cutoff point for
survival data was August 2009.
Treatment Plan and Toxicity Evaluation
Patients received sorafenib (800 mg), and treatment was
continued until disease progression or unacceptable drug-
related toxicities. Dose reduction was allowed for unac-
ceptable toxicities, as previously reported [7]. No
corticosteroids were routinely administered, and those pa-
tients treated with steroids for any reason were excluded.
Tumor response was evaluated every 8 weeks by the use
of consistent imaging techniques (computed tomography or
magnetic resonance imaging). Assessment was performed
by the investigators according to the Response Evaluation
Criteria in Solid Tumors (RECIST).
Patients included in this analysis were categorized on
the basis of their best tumor response as either responders
(patients showing a complete or partial response) or nonre-
sponders (patients with stable or progressive disease or
whose disease status was not assessable). Adverse events
were recorded according to the National Cancer Institute
Common Toxicity Criteria for Adverse Events (NCI-
CTCAE), version 3. Skin toxicity was evaluated and scored
by two independent physicians who separately examined
each patient with a full skin exam. Standardization of skin
toxicity was achieved by the use of the NCI-CTCAE (ver-
sion 3), as previously reported.
Patients were divided into two groups: patients who ex-
perimented at least a grade 1 skin toxicity (considered as
rash and/or HFSR) within the first month of treatment and
those who did not.
Statistical Analysis
Data on treatment activity in the two different groups were
analyzed considering tumor control, defined as the percent-
age of patients who had a best response of complete re-
sponse, partial response, or stable disease (according to the
RECIST) that was maintained for at least 28 days.
TTP was calculated as the period from the beginning of
treatment to the date of the first observation of disease pro-
gression after the start of treatment or the most recent tumor
assessment. TTP was determined by the Kaplan–Meier
product-limit method [8].
Stratified permutation tests were carried out to explore
the association between tumor response and early skin tox-
icity. Moreover, the differences in terms of TTP according
to the presence and severity of skin toxicity were evaluated
by the log-rank test [9]. The Cox proportional hazards
model was applied to the multivariate survival analysis
[10].
The cutoff point for survival data was August 2009.
SPSS software (version 17.00, SPSS, Inc., Chicago, IL)
was used for the statistical analysis. A p-value  .05 was
considered to indicate statistical significance.
RESULTS
Patient Features
We included, in the present analysis, 65 HCC patients
(male/female, 42/23) treated with sorafenib monotherapy.
The median age was 69 years (range, 43–81). Forty-seven
patients (72.3%) received sorafenib after failure of local
treatment (percutaneous ethanol injection, local ablation
therapy such as microwave or radiofrequency ablation,
transcatheter arterial chemoembolization [TACE], and
hepatectomy) whereas 18 patients (27.7%) received it first
line. In 48 patients (73.8%), HCC was limited to the liver,
and in 17 patients (26.2%) HCC involved other organs.
Moreover, 41 patients (63.1%) showed elevated circulating
-fetoprotein levels whereas 24 patients (36.9%) did not. In
52 patients, a viral etiology (HCV or HBV) was confirmed
by standard screening tests. All patients were classified as
CP class A or B. Regarding skin toxicity, 29 patients devel-
oped at least grade 1 skin toxicity within the first month of
sorafenib treatment (rash, 13; HFSR, 16). No patient devel-
oped rash after the first month of treatment, and only three
patients developed HFSR after this period. The incidence of
skin toxicity did not seem to depend upon either the differ-
ent etiologies of liver disease or CP class. Only one patient
in the group of patients with skin toxicity showed a radio-
logical partial response, versus none in the group without
skin toxicity. This difference was not statistically signifi-
cant. The distribution of patients who needed a sorafenib
dose reduction was similar between the group with skin tox-
icity and the group without skin toxicity (20.7% versus
19.4%). Furthermore, in terms of dose delay, no statistically
significant difference was detected between the two groups
(34.5% versus 38.9%). The most common adverse events
that led to drug dose reduction and dose delay were gastro-
intestinal side effects followed by liver dysfunction.
The main characteristics of patients are reported in
Table 2.
Univariate Analysis
In patients who developed early skin toxicity, tumor control
was obtained in 14 patients (48.3%), versus only seven pa-
tients (19.4%) in the group without skin toxicity (p .028).
The median TTP was 8.1 months (95% confidence in-
terval [CI], 6.2–12.1) in the group of patients with early
skin toxicity, versus 4.0 months (95% CI, 2.2–7.0) in pa-
tients who did not develop skin toxicity (p .006; see Fig.
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1). A borderline statistically significant difference (p .09)
was also observed in terms of the OS time in patients with
early skin toxicity, 11.2 months, versus 7.8 months in pa-
tients without skin toxicity. Among the other clinical fac-
tors that could have a predictive value in this population, the
following were analyzed: CP class, previous local treat-
ment, elevated circulating -fetoprotein level, local or met-
astatic disease, and the presence or absence of portal vein
thrombosis. Among these, only disease extension (p .01)
and previous (local) treatments (p  .02) were demon-
strated to be predictive of efficacy with statistical signifi-
cance, as reported in Table 3. No difference in terms of
efficacy was detected in relation to the type of early skin
toxicity (rash versus HFSR).
Multivariate Analysis of Survival
According to a multivariate analysis of TTP, the develop-
ment of early skin toxicity maintained statistical signifi-
cance whereas the other clinical prognostic factors lost their
statistical significance. In detail, the calculated relative risk
for progression in the group of patients with early skin tox-
icity was 0.412 (95% CI, 0.176–0.820), with a p-value of
.02. The relative risk for progression for the group of pre-
viously untreated patients was 0.822 (95% CI, 0.710 –
1.920), when compared with previously treated patients
(p  .802), whereas the relative risk for progression in pa-
tients with only liver involvement was 0.450 (95% CI,
0.415–1.067), when compared with the group of patients
with systemic disease (p .170).
All these data are reported in Table 4.
DISCUSSION
HCC is still considered today to be a highly aggressive dis-
ease. It has been estimated that 22,620 new cases of HCC or
intrahepatic bile duct cancer were diagnosed in 2009 in the
U.S., with approximately 18,160 deaths [11]. In western
countries, chronic HBV infection is the main risk factor,
whereas in Asia and Africa chronic HCV has been proven
to be the most relevant one. Other causes of HCC include
alcoholic liver cirrhosis and aflatoxin exposure [12].
The treatment of HCC represents a challenge for on-
cologists, considering its increase in incidence and the poor
prognosis of the disease.
Partial hepatectomy or transplantation are the only cur-
ative treatments, with a 5-year OS rate of about 50%–70%
[13]. Transplantation is an attractive option for patients af-
fected by early-stage HCC with moderate to severe cirrho-
sis (CP class B or C), because it removes detectable and
undetectable lesions, cures the underlining cirrhosis, and is
not associated with complications resulting from the future
liver remnant. Partial hepatectomy is generally recognized
as the best choice in CP class A patients affected by HCC,
although there are no studies that directly compare the ef-
fectiveness of this approach with that of liver transplant in
this class of patients, whose treatment still remains contro-
versial [14]. In patients not suitable for surgical treatment,
Table 2. Patient features
Feature n %
n of included patients 65 100%
Median age (range) 69 yrs (43–81 yrs) –
Gender
Male 42 64.6%
Female 23 35.4%
Child-Pugh class
A 44 67.7%
B 21 32.3%
HCC etiology
HCV 37 56.9%
HBV 15 23.1%
Unknown (common virus
screening negative)
13 20.0%
Previous treatment
Yes 47 72.3%
No 18 27.7%
Elevated -fetoprotein
Yes 41 63.1%
No 24 36.9%
Disease extension
Liver only 48 73.8%
Metastatic disease 17 26.2%
Portal vein thrombosis
Yes 22 33.8%
No 43 66.2%
Total bilirubin level
2 mg/dl 43 66.2%
2 mg/dl 22 33.8%
Presence of ascites
Yes 17 26.2%
No 48 73.8%
ECOG PS score
0–1 41 63.1%
2 24 36.9%
Albumin level
3.5 mg/dl 39 60%
3.5 mg/dl 26 40%
Abbreviations: ECOG PS, Eastern Cooperative Oncology
Group performance status; HBV, hepatitis B virus; HCC,
hepatocellular carcinoma; HCV, hepatitis C virus.
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chemoembolization and/or ablative procedures have been
suggested on the basis of a meta-analysis demonstrating a
survival advantage [15]. Consistent with these recommen-
dations, two well-designed, randomized trials have shown
that chemoembolization has a positive impact on survival.
Lo et al. [16] randomized patients to receive supportive care
or chemoembolization, finding patient survival rates of
57%, 31%, and 26% in the chemoembolization group ver-
sus 32%, 11%, and 3% in the control group at 1, 2, and 3
years, respectively. A second randomized trial, by Llovet et
al. [17], randomized 112 patients to transarterial emboliza-
tion (TAE), TACE, or supportive care, confirming the clear
survival benefit of TACE and TAE (1- and 2-year survival
rates of 82% and 63% for TACE versus 63% and 27% for
the supportive care group, respectively).
Recently, sorafenib was approved as an appropriate
treatment in patients with advanced HCC: the Sorafenib
Hepatocarcinoma Assessment Randomized Protocol
(SHARP) study pointed out how the median survival time
and time to radiologic progression were nearly 3 months
longer for patients treated with sorafenib than for those in
the placebo group. In the SHARP study, among 602 pa-
tients (299 receiving sorafenib and 303 receiving placebo),
the median OS time was 10.7 months in the sorafenib
group, compared with 7.9 months in the placebo group. The
median time to symptomatic progression was 4.1 months in
the sorafenib group, as compared with 4.9 months in the
placebo group. The median time to radiologic progression
was 5.5 months in the sorafenib group, as compared with
2.8 months in the placebo group [18]. These previous data
were recently confirmed by a phase III study on HCC in an
Asia-Pacific population [19].
Beside its activity, sorafenib seems to be well tolerated:
the principal side effects reported are diarrhea, nausea, fa-
tigue, hypertension, and dermatological toxicities, includ-
ing HFSR, alopecia, stomatitis, erythema, and hemorrhage.
The severity of HFSR is dose related, and depends on
the duration, dosage, and accumulation of the drug [20].
Histologically, HFSR is characterized by thick, well-de-
fined hyperkeratotic lesions frequently affecting digit flex-
ural locations: this peculiar characteristic led to the term
HFSR. Although sorafenib-induced HFSR is usually not a
life-threatening side effect, it affects quality of life in a sig-
nificant manner and can be complicated by infection, pain,
and limitation of activities of daily living. In addition, it rep-
resents a dose-limiting toxicity, and may compromise the
efficacy of the treatment because of dose reduction. A ran-
domized, placebo-controlled, phase III trial called Treat-
Figure 1. Kaplan–Meier survival plot for time to progression according to early skin toxicity.
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ment Approaches in Renal Cancer Global Evaluation Trial,
reported that HFS occurred in approximately 26.0% of pa-
tients. In that trial, dermatological toxicities were the most
frequent cause of dose reduction (13%), interruption (21%),
and discontinuation (10%) [21]. The exact mechanism by
which sorafenib produces painful palm/sole blisters re-
mains unclear, but the higher incidence and greater severity
of rashes at higher doses suggest that it is not the result of an
allergic reaction [22].
The acneiform rash (most often acne-like) usually oc-
curs a few days after administration of sorafenib, and
reaches a maximum after 2–3 weeks from the start of treat-
ment. The characteristic rash is frequently detected on the
face, neck and retroauricular area, scalp, and upper trunk.
The skin lesions consist of sometimes itchy, erythema-
tous follicular papules that may evolve into pustules [23].
The pustules may flow into lakes of pus that evolve into yel-
low crusts [24]. Sometimes the facial lesions consist of
diffuse erythema with follicular papulopustules and telang-
ectasia resembling rosacea. In other cases, a seborrheic der-
matitis-like picture is seen on the face when the pustules
leave an erythema covered with small greasy squames. An
increase in drug concentration in the rich capillary network
at the thickened papillary dermis and resultant increased
blood flow is one of the proposed mechanisms, because the
palms, soles, and fingertips are areas of repeated friction,
grasping, or trauma.
Much experience suggests a possible correlation be-
tween some toxicities related to monoclonal antibodies or
small molecules and response. In advanced colorectal can-
cer, the acne-like rash induced by the epidermal growth fac-
tor receptor inhibitors cetuximab and panitumumab has
been proven to be related to a better outcome [25, 26]. In-
terestingly, among patients with bevacizumab-related hy-
pertension, a significantly superior global clinical outcome
was observed, particularly in terms of the response rate and
TTP (response rate, 75% versus 32%; p  .04. TTP, 14.5
months versus 3.1 months; p .04). No statistically signif-
icant difference was noted for the median OS time. These
results indicate that the development of grade 2–3 hyper-
tension in patients treated with bevacizumab may be an in-
dicator of antitumor activity [27]. These data were
confirmed by the following observations, according to
which the occurrence of hypertension is predictive of a clin-
ical benefit (objective response and stable disease) in the
treatment of metastatic renal cell cancer regardless of the
antiangiogenic used (sunitinib, sorafenib, or bevacizumab)
and regardless of the line of treatment (first or second) [28].
In contrast, there does not seem to be any relationship be-
tween hypertension and the outcome of patients affected by
glioblastoma treated with bevacizumab [29].
With the aim to evaluate the role of early cutaneous tox-
icity as a surrogate marker of efficacy, we performed a ret-
rospective analysis in advanced HCC patients treated with
the multikinase inhibitor sorafenib.
The results of our analysis showed a positive correlation
Table 3. Univariate analysis of TTP
Feature
Median TTP
(95% CI) in mos p-value
Early skin toxicity
Yes 8.1 (6.2–12.1) .006
No 4.0 (2.2–7.0)
Child-Pugh class
A 8.1 (5.1–10.2) .129
B 5.7 (4.2–8.3)
Previous treatment
Yes 4.1 (2.3–7.2) .020
No 8.3 (6.1–10.9)
Elevated -fetoprotein
Yes 6.6 (3.2–8.9) .810
No 7.1 (4.0–10.5)
Disease extension
Metastatic disease 4.2 (2.7–7.1) .012
Liver only 9.0 (5.9–10.1)
Portal vein thrombosis
Yes 5.9 (3.9–7.2) .431
No 7.6 (5.1–10.1)
p-values in bold are statistically significant.
Abbreviations: CI, confidence interval; TTP, time to
progression.
Table 4. Multivariate analysis of TTP
Feature
Relative
risk for
progression 95% CI p-value
Early skin toxicity
No – – .02
Yes 0.412 0.176–0.820
Previous treatment
Yes – – .802
No 0.822 0.710–1.920
Disease extension
Metastatic
disease
– – .170
Liver only 0.450 0.415–1.067
p-value in bold is statistically significant.
Abbreviations: CI, confidence interval; TTP, time to
progression.
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between the early incidence of skin reactions and tumor
control and TTP. Our data seem to confirm the role of early
cutaneous toxicity as a surrogate marker of efficacy similar
to those observed in colorectal cancer [30].
Our results also suggest that the appearance of skin tox-
icity during therapy may indicate antitumor activity: the
identification of a reliable marker of antitumor efficacy
could be extremely useful in clinical practice, in order to
understand the real efficacy of the therapy and, if necessary,
change the treatment strategy early on.
In particular, the results of our study show a relationship
between the development of a rash during sorafenib therapy
and longer TTP and better disease control. A borderline sta-
tistically significant difference was also observed in terms
of OS. The data reported are limited by the retrospective na-
ture of the study and its small size.
CONCLUSION
In our experience, a significantly superior global clinical
outcome was found in patients affected by HCC and treated
with sorafenib who developed a related early skin toxicity.
These results, together with other observations reported
in similar studies employing different biological agents,
suggest that the identification of a reliable clinical factor
such as skin rash developing during different treatments
may constitute an early indicator of antitumor activity. In
contrast, the absence of this side effect might suggest a lack
of antitumor activity of the drug and perhaps suggest a
change in therapy.
Despite these findings, it is right and proper to remem-
ber that HFSR remains a serious toxicity that needs to be
avoided or treated appropriately. The clinical manifestation
and the pathogenesis of HFSR should be evaluated through
collaboration with dermatologists, and a multidisciplinary
approach would help to gain a better understanding and
treatment of this phenomenon.
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